Low-grade serous carcinomas of the ovary contain very few point mutations - Wikidata - awgldk - TriplyDB

Low-grade serous carcinomas of the ovary contain very few point mutations

Low-grade serous carcinomas of the ovary contain very few point mutations

http://www.wikidata.org/entity/Q36415602

about

Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis Recent concepts of ovarian carcinogenesis: type I and type II Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment Pathobiology of ovarian carcinomas Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.ARID1A Is Essential for Endometrial Function during Early Pregnancy Identifying candidate drivers of drug response in heterogeneous cancer by mining high throughput genomics data.Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2 KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Whole exome sequence analysis of serous borderline tumors of the ovary.Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.Ovarian Cancer Is an Imported Disease: Fact or Fiction?Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.Mathematical models of breast and ovarian cancers.Diagnostic potential of tumor DNA from ovarian cyst fluid.Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

P2860

Q26740622-9854099A-EEBA-4B17-AFF8-1A097A9F04B0 Q26776018-1D9C10C8-9B62-45C8-864F-98017B92E1EA Q27009487-13DCCE51-B49D-40A7-B937-A4DF21814827 Q28066904-92A05923-6A88-42DB-A1F0-E083C87EA2D1 Q28080478-A3B26CD1-86CF-4B40-9838-9ADEAA7D579C Q28282973-62B1CF05-A20D-4531-B466-12DDA3E226E8 Q30276986-2D8A5969-29E6-47FF-8163-65EB9B6C78DF Q30370823-E15B55DB-AB4D-4077-A8C3-6F68A18E5B38 Q31121773-70485C25-2762-4392-B3B5-EE45B6B51DC1 Q33570316-C69420BE-85B6-4D07-8A34-6CAFC421B7D1 Q33590020-54E8EEBD-2678-409C-9834-A2DF3BB64058 Q33598001-4E2232F6-32B5-47A6-B82E-FBD6681AE052 Q33853093-5F3E28CE-16F2-42BD-839D-EB765FD47690 Q33862255-CD0DACAD-7E69-4A82-901A-FEC3B833E680 Q33893010-BE368B60-5153-413E-A3A3-09FA486CB42B Q33972424-F433B0E4-D0AB-4EB7-A6E1-790B22BFD7D1 Q33981906-10B7A501-95B2-45FD-92F5-67EA5741B2F9 Q34393919-97B413AC-F4CC-45D5-BDC3-2DAE1B435997 Q34442933-9657A8CC-B840-47F0-8EF3-B8CF9E2431D9 Q34528553-FB6291D6-827A-4327-9ED0-5D375FFACC1A Q35041937-7F95577B-07E2-4D14-92E3-E07E501E2712 Q35060446-953A11F1-8B0E-4D38-9901-E402DB90C300 Q35160677-EBC38681-5645-4E3B-B0CF-AD3E52F302CF Q35598807-F9BDC52F-37D1-4C52-AE99-B685AF826D87 Q35878320-8DB71BB9-79A7-41FC-A512-7F3851C51E47 Q35879961-F4536149-7906-40A6-B619-3B959AA70AF0 Q35947034-359AF6B2-FFB8-493C-86F1-6207D05CF224 Q36346641-B807EE87-0115-4FD1-81C5-DF1DF46002F7 Q36416465-B38D31B6-4495-4D54-BCE2-49D2B867BB3A Q36469640-D31B2D22-F0F2-40BA-8343-70D6607CC7A0 Q36545843-087D4FD4-F8F2-40AE-A335-A1D8D7DA93D3 Q36589374-A708C122-DC18-42DE-97D5-5DF2DC9C60B5 Q36939085-FE7817B9-2084-4589-86EE-E8FBFB6A403A Q37014152-7AC3EFBE-FE94-49F5-A9CF-8709F79CFFE5 Q37098838-5110DE13-F5E1-4187-8270-DCB0E1AEDBB7 Q37376449-0C899DF8-4BDA-4E43-A178-ADF90C590F0E Q37382527-96174F5A-4F13-45DD-B570-BDB096855A9B Q37420213-7DD1A9DB-BAF8-48CA-9488-76A8B4DFC14D Q37624069-B9426267-2E5A-4305-8F65-199AAE68A70A Q37652173-6240D0E6-B4A2-41B2-9B05-1B2A34C6A70B

P2860

Low-grade serous carcinomas of the ovary contain very few point mutations

http://www.wikidata.org/entity/Q36415602

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Low-grade serous carcinomas of the ovary contain very few point mutations

@ast

Low-grade serous carcinomas of the ovary contain very few point mutations

@en

type

label

Low-grade serous carcinomas of the ovary contain very few point mutations

@ast

Low-grade serous carcinomas of the ovary contain very few point mutations

@en

prefLabel

Low-grade serous carcinomas of the ovary contain very few point mutations

@ast

Low-grade serous carcinomas of the ovary contain very few point mutations

@en

P1433

Q36415602-8FA1C6C0-2DEC-4A6C-9702-6901257CAD4A

P1476

Q36415602-C6982029-BC49-4D3B-8CA6-62ADA56BB134

P2093

Q36415602-06A2DA81-D0D5-4EA0-8CB6-5C3BF62FF706

Q36415602-33634207-5EEA-48E6-838D-8D247766235D

Q36415602-40F3EA98-57BE-4CA6-A8B4-15FF0CBB42FB

Q36415602-CC54E4D9-E76E-41E1-B079-15B5A7D55AB1

Q36415602-F8D32E08-494C-45F5-B0AF-2C6DC5671D63

P2860

Q36415602-06746AE4-F26F-4CC5-B4FE-6EAB798CF16A

Q36415602-07FD50FD-CF28-48BC-A2A5-598E5A0C937F

Q36415602-15963122-371B-44C0-95A0-7256E905E212

Q36415602-248D6F05-EFD0-4CDD-9EA8-F0403D2ABC36

Q36415602-33BDD6EB-4585-40E0-A9DF-54733FD3F16A

Q36415602-3FB04241-0BC2-48DE-96CD-140F44B5C750

Q36415602-453C8ACB-98D4-4544-A844-A52C6AE2E1B1

Q36415602-52BC9E2C-529E-4824-9FA3-05CD47298EFD

Q36415602-5F571948-429D-4A18-8AF1-2C08ABB00053

Q36415602-66727FDA-7DBF-4945-A255-FE5085D5078B

P304

Q36415602-887F973C-4B8E-495B-9A32-6880949565EF

P31

Q36415602-3A1F197C-7EA3-46D4-985E-129103B8D693

P356

Q36415602-04B8E884-E665-4F0A-8837-1AF3669C2760

P433

Q36415602-8AAE813F-8D6D-4BF9-B179-8B772E0B18AE

P478

Q36415602-7888E4A9-9E79-42F1-9E18-527A26E0A49A

P50

Q36415602-0907F40D-CAAF-4946-B4FB-78E93327E4D5

Q36415602-228F98ED-A41C-4198-9D28-585036E76914

Q36415602-4A18435D-6023-435E-81C6-02AEAA63F438

Q36415602-FD9875F5-3359-4AF4-8653-4F549CCF1DC1

P577

Q36415602-5C4C1755-6D51-47BA-AFCF-FF3C36544297

P5875

Q36415602-F96AB7B3-608D-4106-BAEE-3F1CD8B0AC86

P698

Q36415602-311F47B1-30EB-4531-BB22-E4DF64DCC6D7

P932

Q36415602-BEDBE11C-76B9-4824-BE4C-F5BE68733FF3

P356

P1433

The Journal of Pathology

P1476

Low-grade serous carcinomas of the ovary contain very few point mutations

@en

P2093

Ie-Ming Shih

http://www.w3.org/2001/XMLSchema#string

Kentaro Nakayama

http://www.w3.org/2001/XMLSchema#string

Nickolas Papadopoulos

http://www.w3.org/2001/XMLSchema#string

Robert J Kurman

http://www.w3.org/2001/XMLSchema#string

Tian-Li Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

ARID1A mutations in endometriosis-associated ovarian carcinomas

Integrated genomic analyses of ovarian carcinoma

Cancer genes and the pathways they control

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

The genetic landscape of the childhood cancer medulloblastoma

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.

P304

413-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.3967

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

226

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth W Kinzler

Victor Velculescu

Bert Vogelstein

P577

2011-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51816573

http://www.w3.org/2001/XMLSchema#string

P698

22102435

http://www.w3.org/2001/XMLSchema#string

P932

3503448

http://www.w3.org/2001/XMLSchema#string